These limitations warrant a need for non-invasive methods of the comprehensive and quantitative assessment of PD-L1 expression and its dynamic change in tumors and metastasis, which may provide better insights for predicting tumor response and monitoring the treatment efficacy of immunotherapies. Here, CD274 is linked to neoplasm.